Veracyte Inc (VCYT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veracyte Inc (VCYT) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($44.76 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Veracyte Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Veracyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VCYT liabilities breakdown for a breakdown of total debt and financial obligations.
Veracyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veracyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FADU Inc.
KQ:440110
|
-0.122x |
|
Newmark Group Inc
NASDAQ:NMRK
|
0.353x |
|
StubHub Holdings, Inc.
NYSE:STUB
|
0.002x |
|
AXT Inc
NASDAQ:AXTI
|
-0.027x |
|
Fabege AB
ST:FABG
|
0.023x |
|
Shantui Construction Machinery Co Ltd
SHE:000680
|
0.030x |
|
Acer Inc
TW:2353
|
-0.033x |
|
Nuvama Wealth
NSE:NUVAMA
|
N/A |
Annual Cash Flow Conversion Efficiency for Veracyte Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Veracyte Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Veracyte Inc (VCYT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.18 Billion | $75.10 Million | 0.064x | +50.77% |
| 2023-12-31 | $1.04 Billion | $44.22 Million | 0.042x | +504.37% |
| 2022-12-31 | $1.08 Billion | $7.54 Million | 0.007x | +124.30% |
| 2021-12-31 | $1.10 Billion | $-31.62 Million | -0.029x | -25.09% |
| 2020-12-31 | $421.23 Million | $-9.71 Million | -0.023x | -70.80% |
| 2019-12-31 | $239.46 Million | $-3.23 Million | -0.013x | +92.04% |
| 2018-12-31 | $79.75 Million | $-13.52 Million | -0.170x | +73.61% |
| 2017-12-31 | $37.23 Million | $-23.91 Million | -0.642x | -36.79% |
| 2016-12-31 | $59.58 Million | $-27.98 Million | -0.470x | +10.73% |
| 2015-12-31 | $51.25 Million | $-26.96 Million | -0.526x | +21.22% |
| 2014-12-31 | $41.37 Million | $-27.63 Million | -0.668x | -96.75% |
| 2013-12-31 | $56.44 Million | $-19.16 Million | -0.339x | +76.79% |
| 2012-12-31 | $4.90 Million | $-7.17 Million | -1.462x | +7.76% |
| 2011-12-31 | $8.53 Million | $-13.52 Million | -1.585x | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more